Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule inhibitors to treat patients with cancer. Its pipeline includes two lead programs: ELVN-001, a small molecule kinase inhibitor in Phase 1 clinical trials for adults with chronic myeloid leukemia, and ELVN-002, a central nervous system penetrant and irreversible HER2 inhibitor in Phase 1 trials for non-small cell lung cancer and HER2 mutant tumors. The company aims to address unmet medical needs in oncology by targeting specific genetic drivers of cancer.

Enliven Therapeutics, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ELVN. The company's shares are traded in US dollars (USD). As a publicly traded biopharmaceutical firm, investors can buy and sell ELVN shares on this major US exchange.

Enliven Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on researching and developing novel small molecule inhibitors for cancer treatment. Biotechnology companies like Enliven use biological processes and molecular biology to create therapies, often targeting specific genetic mutations or pathways involved in disease.

Enliven Therapeutics, Inc. is headquartered in Boulder, Colorado, United States. The company was founded in 2019, making it a relatively young player in the biotechnology space. Its location in Boulder places it within a vibrant life sciences hub, which may provide access to talent, research collaborations, and a supportive ecosystem for drug development.

Enliven Therapeutics' pipeline currently features two clinical-stage programs. ELVN-001 is a small molecule kinase inhibitor in Phase 1 trials for chronic myeloid leukemia in adults. ELVN-002 is a CNS-penetrant and irreversible HER2 inhibitor in Phase 1 trials for non-small cell lung cancer and HER2 mutant tumors. Both candidates are designed to target specific molecular drivers of cancer, potentially offering more precise and effective treatment options for patients.